|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72.82 USD | +0.03% |
|
-.--% | +0.96% |
| 07-14 | Atrium Therapeutics Says FDA Clears Phase 1/2 Trial of ATR 1072 in PRKAG2 Syndrome | MT |
| 05-20 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| Market Cap | 11.3B 9.92B 9.23B 8.49B 15.92B 1,079B 16.19B 110B 42.87B 535B 42.41B 41.5B 1,849B | P/E 2024 |
-10.1x | P/E 2025 | -14.5x |
|---|---|---|---|---|---|
| Enterprise Value | 9.65B 8.47B 7.89B 7.25B 13.6B 922B 13.83B 93.56B 36.62B 457B 36.23B 35.45B 1,580B | EV / Sales 2024 |
181x | EV / Sales 2025 | 492x |
| Free-Float |
96.26% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Avidity Biosciences, Inc.
| 1 day | +0.03% | ||
| 6 months | +0.25% | ||
| Current year | +0.96% |
| Current year | 72 |  | 73.06 |
| 1 year | 34.25 | | 73.06 |
| 3 years | 4.82 | | 73.06 |
| 5 years | 4.82 | | 73.06 |
| 10 years | 4.82 | | 73.06 |
| Manager | Title | Age | Since |
|---|---|---|---|
John McKenna
PSD | President | - | 27/02/2026 |
Eduard Marti
TRE | Treasurer | - | 27/02/2026 |
Jaime S. Huertas
SEC | Corporate Secretary | - | 27/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Jaime S. Huertas
BRD | Director/Board Member | - | 27/02/2026 |
Eduard Marti
BRD | Director/Board Member | - | 27/02/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 2/27/26 A | Issuer sale | Chief Technology Officer | 547,865 | 0.3814% | ||
| 2/27/26 A | Issuer sale | Chief Financial Officer | 721,352 | 0.5021% | ||
| 2/27/26 A | Issuer sale | Chief Technology Officer | 430,990 | 0.3000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | -.--% | +100.77% | +700.22% | 11.3B | |
| +4.20% | +2.96% | +24.44% | -6.82% | 67.88B | |
| +1.79% | +5.13% | +40.44% | +209.42% | 53.23B | |
| +0.26% | +54.90% | +54.90% | +54.90% | 48.71B | |
| +2.69% | -2.52% | -55.39% | -55.35% | 38.98B | |
| +2.73% | +1.21% | +59.04% | -22.48% | 29.55B | |
| +9.30% | +10.68% | +85.19% | +105.94% | 23.75B | |
| +0.31% | -6.46% | +64.57% | -52.97% | 22.07B | |
| +0.62% | -2.81% | +0.84% | +162.10% | 19.84B | |
| +0.60% | +0.82% | +66.12% | +128.15% | 16.57B | |
| Average | +2.27% | +0.36% | +44.09% | +122.31% | 33.19B | |
| Weighted average by Cap. | +2.57% | +1.26% | +35.47% | +75.73% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 10.9M 9.56M 8.91M 8.19M 15.35M 1.04B 15.62M 106M 41.35M 516M 40.91M 40.03M 1.78B | 18.76M 16.46M 15.33M 14.1M 26.43M 1.79B 26.88M 182M 71.17M 889M 70.41M 68.89M 3.07B |
| Net income | -322M -283M -263M -242M -454M -30.79B -462M -3.12B -1.22B -15.27B -1.21B -1.18B -52.76B | -685M -601M -560M -515M -965M -65.41B -981M -6.64B -2.6B -32.44B -2.57B -2.51B -112B |
| Net Debt | -1.49B -1.31B -1.22B -1.12B -2.11B -143B -2.14B -14.49B -5.67B -70.82B -5.61B -5.49B -245B | -1.65B -1.45B -1.35B -1.24B -2.32B -157B -2.36B -15.97B -6.25B -78.06B -6.19B -6.05B -270B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RNA Stock
Select your edition
All financial news and data tailored to specific country editions
